Clinical uncertainty, diagnostic accuracy, and outcomes in emergency department patients presenting with dyspnea.

BACKGROUND Dyspnea is a common complaint in the emergency department (ED) and may be a diagnostic challenge. We hypothesized that diagnostic uncertainty in this setting is associated with adverse outcomes, and amino-terminal pro-B-type natriuretic peptide (NT-proBNP) testing would improve diagnostic accuracy and reduce diagnostic uncertainty. METHODS A total of 592 dyspneic patients were evaluated from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Managing physicians were asked to provide estimates from 0% to 100%of the likelihood of acutely destabilized heart failure (ADHF). A certainty estimate of either 20% or lower or 80% or higher was classified as clinical certainty, while estimates between 21% and 79% were defined as clinical uncertainty. Associations between clinical uncertainty,hospital length of stay, morbidity, and mortality were examined. The diagnostic value of clinical judgment vs NT-proBNP measurement was compared across categories of clinical certainty. RESULTS Clinical uncertainty was present in 185 patients (31%), 103 (56%) of whom had ADHF. Patients judged with clinical uncertainty had longer hospital length of stay and increased morbidity and mortality,especially those with ADHF. Receiver operating characteristic analysis of clinical judgment yielded an area under the curve (AUC) of 0.88 in the clinical certainty group and 0.76 in the uncertainty group (P<.001); NT-proBNP testing alone in these same groups had AUCs of 0.96 and 0.91, respectively. The combination of clinical judgment with NT-proBNP testing yielded improvements in AUC. CONCLUSIONS Among dyspneic patients in the ED, clinical uncertainty is associated with increased morbidity and mortality, especially in those with ADHF.The addition of NT-proBNP testing to clinical judgment may reduce diagnostic uncertainty in this setting.

[1]  S. Marsch,et al.  Use of B-type natriuretic peptide for the management of women with dyspnea. , 2004, The American journal of cardiology.

[2]  Y Wang,et al.  Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. , 1997, Archives of internal medicine.

[3]  J. Hollander,et al.  Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. , 2004, Journal of the American College of Cardiology.

[4]  D. Muthu,et al.  Rapid Measurement of B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart Failure , 2009 .

[5]  A. Maisel,et al.  B-type natriuretic peptides: a diagnostic breakthrough for clinicians. , 2003, Reviews in cardiovascular medicine.

[6]  M. Pfisterer,et al.  Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. , 2004, New England Journal of Medicine.

[7]  C. Schindler,et al.  Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. , 2006, Archives of internal medicine.

[8]  J. Tu,et al.  Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. , 2002, Archives of internal medicine.

[9]  C. Schindler,et al.  Use of B-type natriuretic peptide in the management of acute dyspnea in patients with pulmonary disease. , 2006, American heart journal.

[10]  C. Camargo,et al.  The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. , 2005, The American journal of cardiology.

[11]  Antoni Bayes-Genis,et al.  NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. , 2006, European heart journal.

[12]  C. Gray,et al.  Heart Failure: Improving the Continuum of Care , 2006, Care Management Journals.

[13]  J. Hollander,et al.  B-Type Natriuretic Peptide and Clinical Judgment in Emergency Diagnosis of Heart Failure: Analysis From Breathing Not Properly (BNP) Multinational Study , 2002, Circulation.

[14]  J. Hollander,et al.  Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. , 2003, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[15]  M. Pfisterer,et al.  The use of B‐type natriuretic peptide in the management of elderly patients with acute dyspnoea , 2005, Journal of internal medicine.

[16]  F. Zannad,et al.  Effect of improved disease management strategies on hospital length of stay in the treatment of congestive heart failure. , 1996, Clinical therapeutics.

[17]  A. Hungin,et al.  The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. , 2006, The British journal of general practice : the journal of the Royal College of General Practitioners.

[18]  Sheldon H Gottlieb,et al.  A randomized trial of the efficacy of multidisciplinary care in heart failure outpatients at high risk of hospital readmission. , 2002, Journal of the American College of Cardiology.

[19]  David A Morrow,et al.  BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. , 2004, Congestive heart failure.

[20]  N. Klitgaard,et al.  N‐terminal pro‐brain natriuretic peptide for discriminating between cardiac and non‐cardiac dyspnoea , 2004, European journal of heart failure.

[21]  G. Gazelle,et al.  Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department. , 2006, The American journal of cardiology.

[22]  L. Lenert,et al.  Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. , 2001, Journal of the American College of Cardiology.

[23]  P. Sluss,et al.  The impact of amino-terminal pro-brain natriuretic peptide testing on hospital length of stay and morbidity in patients with acute decompensated heart failure. , 2007, Archives of pathology & laboratory medicine.

[24]  C. Camargo,et al.  Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. , 2006, Archives of internal medicine.